To appraise the clinical and cost effectiveness of DCVax-L for newly diagnosed glioblastoma multiforme.
The company has informed NICE that, at this time, it cannot provide an evidence submission that is required for this appraisal. Therefore, we are suspending the appraisal while we hold further discussions with the company. We will provide a further update and rescheduled timelines in due course.
 
Status Suspended
Process STA pre-2018
ID number 836

Project Team

Project lead Kate Moore

Email enquiries

Consultees

Companies sponsors Northwest Biotherapeutics (DCVax-L)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Brain Tumour Charity
  Brainstrust
  International Brain Tumour Alliance (IBTA)
Professional groups Association of British Neurologists
  Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists

Commentators

General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
19 September 2018 Suspended, The company has informed NICE that, at this time, it cannot provide an evidence submission that is required for this appraisal. Therefore, we are suspending the appraisal while we hold further discussions with the company. We will provide a further update and rescheduled timelines in due course.
19 September 2018 The company has informed NICE that, at this time, it cannot provide an evidence submission that is required for this appraisal. Therefore, we are suspending the appraisal while we hold further discussions with the company. We will provide a further update and rescheduled timelines in due course.
14 June 2018 Invitation to participate
03 April 2018 - 01 May 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
16 August 2017 As you will be aware, the Department of Health has asked NICE to conduct an appraisal of DCVax-L for treating newly diagnosed glioblastoma Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during mid-June 2018 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid-August 2018
26 January 2017 - 23 February 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
22 July 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance